Clinical Trial

The Safety and Efficacy of ZVS106e in the Treatment of IRDs Caused by Biallelic Mutations in ABCA4

Study acronym: ZVS106e
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2026-04-13
Trial Details
NCT Number NCT07241169
Lead Sponsor Zhongshan Ophthalmic Center, Sun Yat-sen University
Collaborators: Chigenovo Co., Ltd
Conditions Stargardt
Enrollment 9 participants
Start Date 2025-12-29
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-16